Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany

Migliori, 2012, Multidrug-resistant tuberculosis in Eastern Europe: still on the increase?, Eur Respir J, 39, 1290, 10.1183/09031936.00214411 D'Ambrosio, 2012, Multidrug-resistant tuberculosis, N Engl J Med, 367, 2154, 10.1056/NEJMc1210001 European Centre for Disease Prevention and Control/WHO Regional Office for Europe, 2014 Special evaluation by Dr. B. Brodhun, Robert Koch-Institute, Berlin, Germany; 2014 October. WHO. Global tuberculosis report 2013. European Medicines Agency, 2013 European Medicines Agency, 2013 Skripconoka, 2012, Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis, Eur Respir J, 41, 1393, 10.1183/09031936.00125812 Diel, 2014, Cost of multi drug resistance tuberculosis in Germany, Resp Med, 108, 1677, 10.1016/j.rmed.2014.09.021 Weinstein, 1996, Recommendations of the Panel on Cost-effectiveness in Health and Medicine, JAMA, 276, 1253, 10.1001/jama.1996.03540150055031 Diel, 2007, Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany, Chest, 131, 1424, 10.1378/chest.06-2728 Sloot, 2014, Risk of tuberculosis after recent exposure: a 10-year follow-up study of contacts in Amsterdam, Am J Respir Crit Care Med, 9, 1044, 10.1164/rccm.201406-1159OC Resch, 2006, Cost-effectiveness of treating multidrug-resistant tuberculosis, PLoS Med, 3, e241, 10.1371/journal.pmed.0030241 Guo, 2009, Measuring health-related quality of life in tuberculosis: a systematic review, Health Qual Life Outcomes, 7, 14, 10.1186/1477-7525-7-14 Salomon, 2012, Common values in assessing health outcomes from disease and injury: disability weights measurement study for the global burden of disease study 2010, Lancet, 380, 2129, 10.1016/S0140-6736(12)61680-8 Fox-Rushby, 2001, Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis, Health Policy Plan, 16, 326, 10.1093/heapol/16.3.326 Diel, 2014, Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs, Pharmacoeconomics, 32, 617, 10.1007/s40273-014-0159-5 McCabe, 2008, The NICE cost-effectiveness threshold: what it is and what that means, Pharmacoeconomics, 26, 733, 10.2165/00019053-200826090-00004 Fitzpatrick, 2012, A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis, PharmacoEconomics, 30, 63, 10.2165/11595340-000000000-00000 Vassall, 26012013 Robert Koch-Institut, 2014 Diacon, 2014, Multidrug-resistant tuberculosis and culture conversion with bedaquiline, N Engl J Med, 371, 723, 10.1056/NEJMoa1313865 Day, 2012, What really happens to tuberculosis patients classified as lost to follow-up in West Yorkshire?, Euro Surveill, 17, 10.2807/ese.17.38.20278-en Diel, 2014, The cost of tuberculosis sequelae, Eur Respir J, 44, 824, 10.1183/09031936.00091414 CDC